Literature DB >> 2770562

Susceptibility of Mycobacterium avium and Mycobacterium intracellulare to various antibacterial drugs.

H Tomioka1, K Sato, H Saito, Y Yamada.   

Abstract

Mycobacterium avium and M. intracellulare of human and natural sources, identified by the Gen-Probe Rapid Diagnostic System for M. avium Complex (MAC) were studied for susceptibility to eight different drugs. In the case of human isolates of MAC, the following was noted. M. avium showed nearly the same susceptibility to streptomycin, kanamycin, ethambutol, and clofazimine as was seen with M. intracellulare. M. avium was much more resistant to rifampicin and rifabutin than was M. intracellulare, and M. avium was more susceptible to quinolones such as ofloxacin and ciprofloxacin. Conversely, in the case of MAC from natural sources, there was no difference between the susceptibility of M. avium and M. intracellulare to these antibacterial agents.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2770562     DOI: 10.1111/j.1348-0421.1989.tb02000.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  8 in total

1.  Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.

Authors:  H Tomioka; K Sato; H Kajitani; T Akaki; S Shishido
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.

Authors:  H Tomioka; K Sato; T Akaki; H Kajitani; S Kawahara; M Sakatani
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

3.  Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice.

Authors:  H Tomioka; H Saito; K Sato; T Yamane; K Yamashita; K Hosoe; K Fujii; T Hidaka
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

4.  Activities of bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice.

Authors:  L E Bermudez; C B Inderlied; P Kolonoski; M Wu; L Barbara-Burnham; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 5.  The Mycobacterium avium complex.

Authors:  C B Inderlied; C A Kemper; L E Bermudez
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

6.  Comparison of the abilities of Mycobacterium avium and Mycobacterium intracellulare to infect and multiply in cultured human macrophages from normal and human immunodeficiency virus-infected subjects.

Authors:  A J Crowle; E R Ross; D L Cohn; J Gilden; M H May
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

Review 7.  Mycobacterium avium in the postgenomic era.

Authors:  Christine Y Turenne; Richard Wallace; Marcel A Behr
Journal:  Clin Microbiol Rev       Date:  2007-04       Impact factor: 26.132

Review 8.  Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; A Fitton
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.